List of Excipients in Branded Drug NILANDRON

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	NILANDRON	nilutamide	59212-111	DOCUSATE SODIUM
Advanz Pharma (US) Corp	NILANDRON	nilutamide	59212-111	LACTOSE
Advanz Pharma (US) Corp	NILANDRON	nilutamide	59212-111	MAGNESIUM STEARATE

Nilandron Excipient Strategy and Commercial Opportunities for Nilutamide

Last updated: September 30, 2026

Nilandron is the U.S. brand for nilutamide, a nonsteroidal antiandrogen approved for metastatic prostate cancer. Its original commercial opportunity is limited by loss of exclusivity, declining clinical use, safety concerns, and competition from bicalutamide, abiraterone, enzalutamide, apalutamide, and darolutamide. The strongest current opportunity is not a conventional branded-generic launch. It is a low-cost, differentiated nilutamide product using excipient reformulation, supply reliability, dose flexibility, or access in jurisdictions where nilutamide remains commercially viable.

The original Nilandron tablet used a conventional immediate-release excipient system based on lactose, corn starch, povidone, magnesium stearate, and talc. A modern product could target lactose intolerance, swallowing difficulty, tablet disintegration, global-market manufacturing, or reduced packaging and distribution cost. New excipient patents would have limited blocking power unless linked to a clinically meaningful formulation or delivery advantage.

What is Nilandron and what is the active pharmaceutical ingredient?

Nilandron contains nilutamide, an androgen-receptor antagonist. It was approved in the United States for use with surgical castration in patients with metastatic prostate cancer. The labeled regimen is 300 mg once daily for the first 30 days, followed by 150 mg once daily.[1]

Attribute	Nilandron
Active ingredient	Nilutamide
Drug class	Nonsteroidal antiandrogen
Original sponsor	Roussel Uclaf, later associated with Sanofi
Dosage form	Immediate-release oral tablet
U.S. strength	150 mg
Initial dosing	300 mg daily for 30 days
Maintenance dosing	150 mg daily
Primary indication	Metastatic prostate cancer
FDA approval	1990s
Key safety issues	Interstitial pneumonitis, hepatotoxicity, visual adaptation problems, alcohol intolerance
Current commercial position	Mature, discontinued or limited brand market; generic and regional opportunities depend on current regulatory listings

Nilutamide blocks androgen-receptor signaling but does not reduce androgen production. Its clinical use declined as newer androgen-receptor pathway inhibitors and androgen-deprivation combinations became standard in broader prostate-cancer treatment settings.[2]

What excipients are used in Nilandron tablets?

The Nilandron labeling identifies a conventional tablet formulation containing lactose, corn starch, povidone, magnesium stearate, and talc.[1] These excipients support tablet compression, granulation, lubrication, and powder flow.

Excipient	Likely formulation function	Commercial implication
Lactose	Diluent and compression aid	Creates an opportunity for lactose-free reformulation
Corn starch	Filler and disintegrant	Supports immediate release and low-cost manufacture
Povidone	Binder	Useful for wet granulation and mechanical strength
Magnesium stearate	Lubricant	Excessive use can slow dissolution
Talc	Glidant or anti-adherent	May be removed or replaced for process and market preferences

The original excipient profile is commercially ordinary. It does not create a meaningful formulation moat by itself. A generic manufacturer could generally use a different inactive-ingredient system, subject to FDA inactive-ingredient requirements, pharmaceutical equivalence, bioequivalence, stability, and product-quality controls.[3]

What formulation characteristics matter for nilutamide?

Nilutamide is administered as a conventional oral tablet and does not require a complex delivery platform. The main formulation targets are:

1. Immediate and reproducible drug release.
2. Adequate content uniformity at the 150 mg strength.
3. Mechanical strength during packaging and transport.
4. Acceptable tablet size for long-term cancer treatment.
5. Stability under global temperature and humidity conditions.
6. Compatibility with patients who cannot tolerate lactose or have difficulty swallowing.

Because the labeled loading regimen requires two 150 mg tablets daily for 30 days, tablet count and adherence are relevant commercial factors. A 300 mg tablet could reduce pill burden, but it would require a new product-development and regulatory strategy and might not be interchangeable with the existing 150 mg presentation.

What excipient strategies could differentiate a nilutamide product?

The strongest excipient strategy is a lactose-free immediate-release tablet with robust dissolution and improved manufacturability.

Lactose-free reformulation

Replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, partially pregelatinized starch, or another suitable diluent could address patients with lactose intolerance and simplify positioning in markets that prefer lactose-free products.

A lactose-free formulation would be commercially differentiated only if the manufacturer can support the claim with:

• Verified inactive-ingredient disclosure.
• Comparable dissolution.
• Bioequivalence or an applicable regulatory bridge.
• Stable long-term storage.
• Clear patient and pharmacist labeling.

The value is likely modest because lactose intolerance is not the principal barrier to nilutamide use. It can still help a generic manufacturer win hospital, specialty-pharmacy, or tender business.

Direct-compression formulation

A direct-compression platform could replace wet granulation and reduce process steps. Microcrystalline cellulose, spray-dried mannitol, anhydrous dibasic calcium phosphate, crospovidone, and low-level magnesium stearate are potential components.

The principal development risks are powder flow, segregation, tablet capping, dissolution variability, and scale-up reproducibility. A process patent could protect a validated manufacturing method, but its commercial value would depend on whether the method materially reduces cost or improves supply reliability.

Low-dose excipient optimization

Nilutamide is used at a 150 mg tablet strength, so the formulation is not a classic low-dose content-uniformity problem. However, excipient selection still affects tablet weight, size, friability, and dissolution. A compact tablet can reduce packaging volume and shipping costs, but a smaller tablet must remain easy to handle and distinguish from other oral oncology products.

Swallowing-focused formulation

Film coating, smooth tablet geometry, and reduced tablet dimensions may improve swallowing. An orally disintegrating tablet, orally dispersible tablet, or liquid suspension could offer stronger differentiation, but those products would face additional development risks:

• Taste masking.
• Dose uniformity.
• Stability after reconstitution.
• Packaging complexity.
• Higher manufacturing cost.
• Potentially greater regulatory scrutiny.

For a low-demand legacy antiandrogen, these investments are unlikely to be attractive without a defined institutional or geographic market.

What patents protect Nilandron and nilutamide?

Nilutamide’s core composition-of-matter protection is expired. The original Nilandron market is therefore not protected by a current active-ingredient patent barrier in the United States.

IP category	Current commercial relevance
Nilutamide composition patent	Expired
Original Nilandron product protection	Expired or no longer commercially material
Immediate-release tablet formulation	Limited blocking value unless a narrow unexpired claim exists
Method-of-use patents	Limited relevance because the original metastatic-prostate-cancer use is established
Manufacturing patents	Potentially relevant for a new process, but unlikely to block ordinary generic manufacture
New excipient formulation patents	Possible, but protection would depend on specific composition and performance claims
Delivery-system patents	Possible for ODT, liquid, multiparticulate, or modified-release products

A reformulated nilutamide product could obtain patent protection for a specific composition, dissolution profile, manufacturing process, or patient-use method. Such patents would protect the new product, not revive exclusivity for the original Nilandron tablet.

When did Nilandron lose exclusivity?

Nilandron lost meaningful U.S. market exclusivity years ago. The relevant commercial issue is not patent expiration but whether a sponsor can obtain or maintain a viable regulatory listing and secure enough demand to support manufacture.

The U.S. product has been treated as a discontinued product in FDA drug databases. A discontinued listing does not by itself establish that the product was withdrawn for safety reasons. It indicates that the listed product is no longer marketed under that application or presentation.[4]

What is the Orange Book status of Nilandron?

The FDA Orange Book distinguishes active marketed products from products that have been discontinued. Nilandron’s current commercial status must be assessed through the latest Orange Book and FDA drug-listing records because product availability and manufacturer status can change.

For a launch assessment, the relevant checks are:

• Whether an active Nilandron reference listed drug remains available.
• Whether an approved ANDA for nilutamide 150 mg exists.
• Whether the reference product is designated as discontinued.
• Whether an ANDA applicant can demonstrate bioequivalence to an eligible reference.
• Whether FDA requires a suitability petition, new drug application, or other pathway because the reference product is unavailable.

A discontinued brand listing can create regulatory complexity. It does not automatically create a free path for a generic applicant.

Are there Paragraph IV challenges to Nilandron?

Nilandron is not a major current Paragraph IV litigation target because its core patent estate is historically expired and its commercial market is small. A Paragraph IV certification would be relevant only if an applicant were addressing a listed unexpired patent associated with a reference product or an approved formulation.

The more likely regulatory risks are:

• Reference-product availability.
• Bioequivalence strategy.
• Product-specific FDA requirements.
• Small projected market size.
• Manufacturing economics.
• Pharmacovigilance obligations for a product with known pulmonary and hepatic risks.

There is no strong commercial basis to assume an active, material Paragraph IV dispute around the original Nilandron tablet without a current patent listing and litigation record.

What generic launch opportunities exist for nilutamide?

The generic opportunity is niche and geography-dependent.

United States

A U.S. generic could target:

• Patients maintained on nilutamide who need continued supply.
• Specialty pharmacies.
• Oncology practices with established prescribing patterns.
• Institutional buyers seeking a low-cost alternative.
• Patients for whom switching to another antiandrogen is clinically undesirable.

The market would likely be small. A sponsor would need to control manufacturing costs, avoid excess inventory, and establish reliable distribution. A single-source or limited-source market can support pricing above commodity generic levels, but demand volatility creates inventory risk.

Europe and other markets

Nilutamide’s commercial viability may be stronger in countries where:

• It remains authorized.
• National reimbursement includes the product.
• Physicians continue using older antiandrogen regimens.
• Newer androgen-receptor inhibitors are less accessible.
• Local manufacturing or tender supply supports lower cost.

The same excipient reformulation could support multiple jurisdictions if the manufacturer aligns inactive-ingredient declarations, stability data, dissolution specifications, and local labeling requirements.

Hospital and tender markets

A lactose-free product may improve eligibility for hospital formularies, but it is unlikely to win tenders alone. Price, supply continuity, batch-release performance, and regulatory status will matter more than excipient differentiation.

How strong is the nilutamide patent estate?

The original nilutamide patent estate is weak as a barrier to entry because the active ingredient and original product exclusivity are mature. A new sponsor could build a narrow secondary estate around:

• Lactose-free tablet composition.
• Specific disintegrant and lubricant ratios.
• Enhanced dissolution under biorelevant conditions.
• High-humidity stability.
• Direct-compression manufacturing.
• Smaller tablet geometry.
• 300 mg loading-dose presentation.
• Orally dispersible or liquid dosage forms.

The enforceability of these claims would depend on technical evidence and claim breadth. A patent covering only routine excipient substitution would face meaningful validity and obviousness risk. A formulation patent is stronger when it demonstrates an unexpected dissolution, stability, bioavailability, or manufacturing result.

What manufacturing and IP barriers affect nilutamide?

Nilutamide does not require biologic manufacturing, sterile filling, complex conjugation, or a specialized device. The manufacturing barrier is therefore moderate to low.

The principal barriers are commercial and regulatory:

Barrier	Impact
Small patient population	Limits manufacturing scale
Discontinued or limited reference product	Complicates generic development
Pulmonary and hepatic safety profile	Increases pharmacovigilance burden
Legacy supply chain	May require new API and excipient qualification
Low prescription volume	Raises unit cost
Global registration differences	Increases dossier and stability costs
Competition from newer agents	Restricts pricing power

Nilutamide API sourcing and impurity control remain important. The manufacturer should qualify at least one reliable API source and establish controls for degradation products, residual solvents, polymorphic form, particle-size distribution, and assay uniformity.

How does nilutamide compare with competing prostate-cancer drugs?

Drug	Commercial position	Relative advantage over nilutamide
Bicalutamide	Established generic antiandrogen	Broader familiarity and often stronger supply
Flutamide	Older generic antiandrogen	Similar legacy positioning but significant hepatic concerns
Abiraterone	Generic androgen-synthesis inhibitor	Stronger contemporary treatment relevance in many settings
Enzalutamide	Branded and generic-market product in some regions	Stronger modern androgen-receptor pathway positioning
Apalutamide	Newer androgen-receptor inhibitor	Broader contemporary clinical use
Darolutamide	Newer androgen-receptor inhibitor	Favorable differentiation in selected patients
Nilutamide	Legacy, niche antiandrogen	Low cost and established historical use, but limited momentum

Nilutamide’s main competitive advantage is potential price and availability in markets where newer agents are unaffordable or inaccessible. Its disadvantages are safety concerns, limited contemporary prescribing, and weaker clinical differentiation.

What commercial model is most attractive for a nilutamide product?

The most viable model is a focused generic or regional supply product rather than a high-investment specialty formulation.

Base-case strategy

• Launch a 150 mg lactose-free immediate-release tablet.
• Use direct compression or a simplified granulation process.
• Maintain a conventional film coat.
• Secure a low-cost API source.
• Target jurisdictions with active nilutamide demand.
• Sell through specialty distribution and institutional channels.
• Avoid broad claims that the product is clinically superior without evidence.

Higher-value strategy

A sponsor could develop a 300 mg loading-dose tablet to reduce pill burden during the first 30 treatment days. This would create a clearer product distinction but would require additional formulation, stability, labeling, and regulatory work. The opportunity is attractive only if the sponsor can identify enough new and continuing patients to offset development expense.

Low-probability strategy

An orally disintegrating or modified-release formulation could obtain stronger patent protection but would likely face unfavorable economics. The incremental clinical value is uncertain, while development cost and regulatory complexity would rise materially.

What litigation and settlement risks affect Nilandron?

No material current patent-litigation risk should be assumed for the original Nilandron tablet absent an active Orange Book-listed patent and a live case involving a generic applicant. The more relevant legal issues are:

• Patentability of a new excipient formulation.
• Freedom to operate around third-party tablet technologies.
• Trademark clearance for a new product name.
• Product-liability exposure related to pulmonary and hepatic warnings.
• Distribution obligations for a discontinued or limited-supply reference product.
• Regulatory consequences of changing excipients or dosage strength.

A settlement agreement would be relevant only if a new formulation patent generated an active ANDA dispute. There is no commercial basis to treat historical Nilandron exclusivity as a current settlement-driven launch constraint.

Key Takeaways

• Nilandron is nilutamide, an old nonsteroidal antiandrogen with a mature and weak original patent position.
• The original formulation used lactose, corn starch, povidone, magnesium stearate, and talc.
• A lactose-free immediate-release tablet is the most practical excipient strategy.
• Direct compression could reduce manufacturing cost but would need dissolution and scale-up validation.
• A 300 mg loading-dose tablet could reduce pill burden but requires a separate development and regulatory assessment.
• Core patent and exclusivity barriers are expired or commercially immaterial.
• Paragraph IV litigation is unlikely to be the primary launch issue.
• The largest risks are limited demand, reference-product status, safety monitoring, API supply, and competition from newer prostate-cancer therapies.
• The best opportunity is a low-cost, reliable, geographically targeted generic or regional product.
• Broad reformulation investment is difficult to justify without identified demand, reimbursement, or institutional procurement support.

FAQs

Is nilutamide still commercially available?

Availability is jurisdiction-specific. The U.S. Nilandron brand has been listed as discontinued or commercially limited, while nilutamide may remain available in selected international markets.

Can a generic manufacturer replace lactose in nilutamide tablets?

Yes. A generic manufacturer may use a different excipient system if the product satisfies applicable quality, dissolution, stability, inactive-ingredient, and bioequivalence requirements.

Does nilutamide have active composition-of-matter patent protection?

No material active-ingredient exclusivity should remain for the original nilutamide product. Any new protection would likely relate to a specific formulation, manufacturing process, or new use.

Would a 300 mg nilutamide tablet have commercial value?

It could reduce tablet burden during the initial 300 mg daily dosing period. Its value would depend on the size of the treated population and the regulatory cost of adding a new strength.

Is an orally disintegrating nilutamide tablet commercially attractive?

It offers differentiation but probably has limited economic appeal. The patient population is small, and the product would incur taste-masking, stability, manufacturing, and regulatory costs without a clear clinical advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Nilandron (nilutamide) tablets: Prescribing information.
2. National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Prostate cancer.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and discontinued drug product records.